Dislocation

Figures converted from Israeli shekels (₪) at historical FX rates — see data/company.json.fx_rates. NICE reports its financial results in US dollars, so revenue, EPS, and guidance figures are unchanged; only the shekel share-price levels are converted (at ₪→$ 0.32641, applied uniformly so the −40.56% drawdown is preserved). Ratios, margins, and multiples are unitless and unchanged.

Dislocation — what exactly happened to the price

There is a real dislocation, with a dated trigger. NICE fell 40.6% from its 5-March-2026 peak ($135.2) to a 19-June trough ($80.4), and sits at $95.2 — 29.6% below the high. The event leg was the 6-May Q1 2026 report: a revenue and EPS beat with raised full-year EPS guidance, sold off 18.8% in one session on a soft Q2 growth guide and AI-driven retention pressure. The price fall far outran the estimate change.

NICE reports its financial results in US dollars but its shares trade in shekels on the Tel Aviv Stock Exchange (with NASDAQ ADRs). Price and drawdown figures below are shekel closes converted to dollars; revenue, EPS, and guidance are in $ as the company reports them. The companion page shows the native shekel price levels.

The drawdown — a 41% fall in one quarter, with a clean event leg

Source: daily price history, TASE close (data/prices/daily.json), converted to USD; drawdown levels and −40.56% depth per the deterministic feature file (fit_features.capitulation_gauge.drawdown).

The peak-to-trough fall of 40.6% took 106 days and ran in two distinguishable phases. From the 5-March high of $135.2, the stock drifted down to about $99 by late April — a 27% decline with no NICE-specific event and only moderate volume, the kind of drift the framework treats as the start of the slide rather than the moment. It then spiked 21.3% to $121.6 on 4 May on reports that NICE had drawn roughly $2.5 billion of bids for its Actimize financial-crime unit [1]. Two sessions later the event leg hit: a single-day 18.8% collapse on 6 May that reset the trend and carried price to the $80.4 trough on 19 June before a partial recovery to $95.2.

A caution on the raw series: the price feed is a six-month web-sourced history (23 January to 21 July 2026), so the $135.2 "peak" is the high of this window, not a verified multi-year top, and the 180-day pre-peak baseline used for the volume gauge is truncated to about 30 trading days. The percentage drawdown is robust to these limits; the absolute price levels should be read as the feed reports them.

The trigger — a beat-and-raise the market sold 18.8%

The dated adverse event is the first-quarter 2026 report, released 6 May 2026 before the US open [2]. On its face the print was strong. Revenue of $768.6 million rose 9.8% and beat consensus by 1.0%; non-GAAP EPS of $2.64 beat by 4.8%; both cleared the high end of guidance, and management raised full-year EPS guidance to $10.98–$11.18 [3]. AI ARR grew 66% year over year to $345 million. Against that, the stock fell from a $120.7 intraday high to a $93.7 low, closing down 18.8%.

Source: reported actuals, Q1 2026 press release [4]; consensus as-of from CapIQ estimates (data/sp/estimates.json, beat_miss).

What repriced the stock was the forward setup, not the quarter. Three items in the same release and call carried the signal:

• Second-quarter revenue guidance of $761–771 million implies just 5.5% year-over-year growth at the midpoint — a sharp step down from the 9.8% just reported [5]. Full-year cloud growth was guided to 13%–15% [6], well below the roughly 25% cloud growth NICE ran two years earlier.
• Cloud net revenue retention fell to 107%. The CFO tied it directly to the AI transition: "we are seeing some near term pressure on NRR as we continue to transition our portfolio towards AI driven capabilities which can result in compression in certain CX components" [7].
• Pricing concessions to marquee accounts created a Q2 timing hole: management took "renewal specific commercial actions to accelerate AI expansion," producing "phasing effects… with a more pronounced impact expected in Q2," so Q2 cloud growth would run "slightly below our full year range" [8].

The mechanism behind the fear is concrete: agentic AI displaces the human contact-center seats NICE has historically billed against, and the AI ARR growing at 66% is not yet large enough (14% of cloud) to offset the seat compression showing up in retention. Organic cloud growth, stripping out the Cognigy acquisition, was closer to 12% than the headline 14.6% [9]. The market repriced NICE's growth trajectory and multiple, not its 2026 earnings line — which management raised.

This is not the first time. The identical pattern — a beat overwhelmed by a soft cloud guide and AI-substitution worry — drove a roughly 20% single-quarter plunge in November 2025 and a plunge on the February 2025 outlook [10]. The 6-May move is the latest and largest instance in the corpus, and it is the leg that defines this drawdown.

The fear gauge — capitulation volume, clustered late in the fall

Source: daily volume (data/prices/daily.json); spike multiples per the feature file (fit_features.capitulation_gauge.volume_spike) and data/tech/unusual_volume.json.

The volume did spike, and the measured multiple is 3.3x — the peak-to-trough leg's heaviest 20-day average volume against the median daily volume of the 180 days before the peak (fit_features.capitulation_gauge.volume_spike). Two features matter for reading it as emotion-driven rather than orderly. First, the event day itself (6 May) traded 665,650 shares, 2.83x its 50-day average, confirming forced repricing on the news [11]. Second, and more telling, the single heaviest session of the entire window was 29 May at 4.73 million shares — 13.8x the 50-day average — on a close of $81.6 that moved only −3.0%. High volume with almost no price change, arriving near the trough rather than at the March top, is the washout signature: the marginal seller was being cleared out late in the fall, consistent with the framework's "peak fear, not the start of the slide." (The May-29 anomaly is also consistent with index-rebalancing flow, though the corpus does not confirm a specific index event.)

Who was selling — a data gap on shorts, and a company buying its own fall

Official short-interest data is not available for a TASE-listed security in this run: no deterministic public short-interest source is configured for Israel, and the latest snapshot returns status "unavailable" (data/short_interest/latest.json). Short-interest level and change cannot be quantified here — a genuine gap, not a zero.

What the record does show is that the largest identifiable buyer through the drawdown was the company itself. NICE repurchased a record $253 million of stock in Q1 2026 — about 3.5% of its market capitalization — cutting weighted diluted shares roughly 5% year over year to about 58.5 million, and exited the quarter with $745 million of buyback authorization remaining and a commitment to repurchase more than 50% of free cash flow for the year [12]. On the seller side, the recurring "sell-the-guide" reaction across three consecutive outlook events (Feb 2025, Nov 2025, May 2026) points to a holder base that repeatedly repositions on decelerating cloud guidance rather than to a single forced liquidation [13]. No fund liquidation, index exit, or insider sale is disclosed in the corpus. The seller composition is therefore best described as anchored, guidance-reactive selling against a heavy corporate bid — with the short leg unquantifiable.

Estimates versus price — the fall outran the cut

This is the framework's signature, and it is pronounced here. Across the drawdown, forward estimates barely moved while price fell 40.6%. Full-year 2027 revenue consensus was trimmed only 1.3%, from $3,532 million in January to $3,486 million by June; over the same span, 2027 EPS consensus was revised up 5.1%, from $12.49 in April to $13.13 by July (CapIQ consensus). At the event itself the company raised full-year 2026 EPS guidance to $10.98–$11.18 rather than cutting it [14], and consensus 2026 EPS sits near $11.11, inside that raised range.

Source: price per fit_features.capitulation_gauge; estimate revisions from CapIQ momentum series (data/sp/estimates.json), FY2027 revenue and normalized EPS.

Consensus estimates fell fractionally, and after — not before — the price; the near-term FCF path dips modestly (FY2026 consensus FCF $589.8 million against FY2025's $648.6 million) before reaccelerating to $694.8 million in FY2027, per CapIQ consensus. A price that fell 40.6% while forward EPS estimates were flat-to-higher is a fall driven by multiple compression, not by the earnings the sell side actually forecasts. Whether that compression is deserved — whether AI-driven seat displacement permanently impairs NICE's economics or merely reprices one year — belongs to the Damage Math tab and the trial, not here.

Bottom line

NICE presents a genuine dislocation with a dated trigger and capitulation volume: a 40.6% peak-to-trough fall whose defining leg was the 18.8% single-session drop on the 6-May-2026 Q1 report — a revenue-and-EPS beat with raised full-year EPS guidance, sold off on a 5.5% Q2 revenue guide, cloud growth decelerating to 13%–15%, and net-revenue-retention compression the CFO attributed to the AI transition. Volume spiked 3.3x with the heaviest, lowest-price-change session near the trough. Forward estimates fell only low-single-digits — EPS actually rose — so the price fall clearly outran the estimate change. The unquantifiable short-interest picture and the six-month, shekel-denominated price feed are the honest caveats.